​

Kiniksa Pharmaceuticals International (KNSA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KNSA Stock Forecast

Kiniksa Pharmaceuticals International (KNSA) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $70.80, with a high of $75.00 and a low of $62.00. This represents a 12.67% increase from the last price of $62.84.

$15 $27 $39 $51 $63 $75 High: $75 Avg: $70.8 Low: $62 Last Closed Price: $62.84

KNSA Stock Rating

Kiniksa Pharmaceuticals International stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

KNSA Price Target Upside V Benchmarks

TypeNameUpside
StockKiniksa Pharmaceuticals International12.67%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts3511
Avg Price Target$73.67$70.20$61.27
Last Closing Price$62.84$62.84$62.84
Upside/Downside17.23%11.71%-2.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2617---8
Jun, 2617---8
May, 2617---8
Apr, 2617---8
Mar, 2617---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 23, 2026Paul ChoiGoldman Sachs$75.00$62.4420.12%19.35%
Jul 13, 2026Wells Fargo$74.00$63.4416.65%17.76%
Jun 29, 2026Wedbush$72.00$59.2021.62%14.58%
Apr 29, 2026Wedbush$59.00$53.859.56%-6.11%
Apr 28, 2026Roger SongJefferies$71.00$53.8031.97%12.99%
Apr 16, 2026Wedbush$58.00$46.2525.41%-7.70%
Feb 19, 2026Canaccord Genuity$62.00$45.3936.59%-1.34%
Jan 13, 2026David NierengartenWedbush$50.00$39.6526.10%-20.43%
Oct 29, 2025Goldman Sachs$55.00$37.8145.46%-12.48%
Oct 13, 2025Wedbush$44.00$37.8916.13%-29.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2026Goldman SachsBuyBuyhold
Jul 13, 2026Wells FargoOverweightOverweighthold
Jun 29, 2026WedbushOutperformOutperformhold
Apr 29, 2026CitigroupBuyBuyhold
Apr 28, 2026JefferiesBuyBuyhold
Apr 16, 2026WedbushOutperformOutperformhold
Jan 13, 2026WedbushOutperformOutperformhold
Jan 06, 2026Cowen & Co.BuyBuyhold
Oct 29, 2025Goldman SachsBuyBuyhold
Oct 22, 2025Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.30$2.64$0.20$-0.60$0.80---
Avg Forecast$-2.18$2.38$-0.17$-0.39$0.56$0.83$1.45$0.77
High Forecast$-2.13$2.48$-0.15$-0.29$1.26$1.24$1.91$0.81
Low Forecast$-2.29$2.31$-0.19$-0.43$0.05$0.47$1.12$0.74
Surprise %5.50%10.92%-217.65%53.85%42.86%---

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$38.54M$220.18M$270.26M$423.24M$677.56M---
Avg Forecast$37.40M$203.34M$260.12M$424.18M$578.12M$683.58M$802.31M$845.00M
High Forecast$38.77M$210.11M$260.98M$424.42M$584.28M$708.11M$803.74M$875.33M
Low Forecast$36.65M$198.96M$259.26M$423.70M$569.27M$664.88M$800.88M$821.89M
Surprise %3.06%8.28%3.90%-0.22%17.20%---

Net Income Forecast

$-200M $-120M $-40M $40M $120M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-157.92M$183.36M$14.08M$-43.19M$118.73M---
Avg Forecast$-163.10M$-141.18M$14.08M$-25.95M$33.35M$55.73M$87.68M$55.38M
High Forecast$-130.48M$-112.94M$16.90M$-21.16M$90.76M$89.02M$137.72M$57.96M
Low Forecast$-195.71M$-169.41M$11.27M$-30.73M$3.24M$34.11M$80.34M$53.41M
Surprise %-3.17%-229.88%-66.46%256.02%---

KNSA Forecast FAQ

Is Kiniksa Pharmaceuticals International stock a buy?

Kiniksa Pharmaceuticals International stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kiniksa Pharmaceuticals International is a favorable investment for most analysts.

What is Kiniksa Pharmaceuticals International's price target?

Kiniksa Pharmaceuticals International's price target, set by 11 Wall Street analysts, averages $70.8 over the next 12 months. The price target range spans from $62 at the low end to $75 at the high end, suggesting a potential 12.67% change from the previous closing price of $62.84.

How does Kiniksa Pharmaceuticals International stock forecast compare to its benchmarks?

Kiniksa Pharmaceuticals International's stock forecast shows a 12.67% upside, underperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for Kiniksa Pharmaceuticals International over the past three months?

  • July 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Kiniksa Pharmaceuticals International’s EPS forecast?

Kiniksa Pharmaceuticals International's average annual EPS forecast for its fiscal year ending in December 2026 is $0.83, marking a 3.75% increase from the reported $0.8 in 2025. Estimates for the following years are $1.45 in 2027, and $0.77 in 2028.

What is Kiniksa Pharmaceuticals International’s revenue forecast?

Kiniksa Pharmaceuticals International's average annual revenue forecast for its fiscal year ending in December 2026 is $683.58M, reflecting a 0.89% increase from the reported $677.56M in 2025. The forecast for 2027 is $802.31M, and $845M for 2028.

What is Kiniksa Pharmaceuticals International’s net income forecast?

Kiniksa Pharmaceuticals International's net income forecast for the fiscal year ending in December 2026 stands at $55.73M, representing a -53.06% decrease from the reported $118.73M in 2025. Projections indicate $87.68M in 2027, and $55.38M in 2028.